GL-ONC1

Phase 1/2Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Peritoneal Carcinomatosis

Conditions

Peritoneal Carcinomatosis

Trial Timeline

Feb 1, 2012 → Sep 1, 2014

NCT ID

NCT01443260

About GL-ONC1

GL-ONC1 is a phase 1/2 stage product being developed by Genelux for Peritoneal Carcinomatosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01443260. Target conditions include Peritoneal Carcinomatosis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03420430	Pre-clinical	Completed	—	—	Advanced Stage Cancer (Solid Tumor Disease for 4 Patients)
NCT02714374	Phase 1	Terminated	Mar 25, 2016	Aug 6, 2019	Solid Organ Cancers
NCT01766739	Phase 1	Completed	Jan 1, 2013	Oct 24, 2024	Lung Cancer
NCT01584284	Phase 1	Completed	Apr 1, 2012	Jul 1, 2015	Cancer of Head and Neck
NCT01443260	Phase 1/2	Completed	Feb 1, 2012	Sep 1, 2014	Peritoneal Carcinomatosis
NCT00794131	Phase 1	Completed	Nov 1, 2008	Nov 1, 2015	Advanced Cancers (Solid Tumors)

Competing Products

20 competing products in Peritoneal Carcinomatosis

See all competitors

Product	Company	Stage	Hype Score
azenosertib	Zentalis Pharmaceuticals	Phase 2	44
MCY-M11 + Cyclophosphamide	MaxCyte	Phase 1	25
R744 + R744	Chugai Pharmaceutical	Phase 3	77
roxadustat	Astellas Pharma	Phase 3	77
Abemaciclib	Eli Lilly	Phase 1	33
M200 (Volociximab) + Liposomal Doxorubicin + M200 (Volociximab) + M200 (Volociximab)	AbbVie	Phase 1/2	41
Adavosertib + Paclitaxel + Carboplatin + Gemcitabine + PLD	AstraZeneca	Phase 2	52
Tremelimumab + Olaparib	AstraZeneca	Phase 1	33
ertapenem	Merck	Approved	85
Octreotide LAR + Octreotide (Immediate release) + methylprednisolone + Placebo	Novartis	Phase 2	52
PA21	Kissei Pharmaceutical	Phase 3	76
PF-06873600 + Endocrine Therapy 1 + Endocrine Therapy 2	Pfizer	Phase 1/2	40
Bevacizumab + Nivolumab + Rucaparib	Bristol Myers Squibb	Phase 2	51
Iniparib	Sanofi	Phase 2	51
Sevelamer Hydrochloride (Renagel®) + Calcium acetate (PhosLo® )	Sanofi	Phase 3	76
nanoliposomal irinotecan	Ipsen	Phase 1	30
Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution	Baxter	Approved	82
Anti-Adhesion Product	Baxter	Phase 2	49
Pioglitazone	Baxter	Pre-clinical	20
Icodextrin Peritoneal Dialysis Solution + Hypertonic Dextrose solution	Baxter	Approved	82

Other Products from Genelux

olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin (preferred) or cisplatin + Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin + Bevacizumab (or biosimilar)Phase 3

Olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin or cisplatin + Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC + Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab + DocetaxelPhase 2

Olvi-Vec + platinum (cisplatin or carboplatin) + EtoposidePhase 1/2

GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumabPhase 1/2

GL-ONC1Phase 1